CCX832 is an orally active molecule antagonist of chemerin at the chemokine receptor CMKLR1(ChemR2). ChemoCentryx a pharmaceutical firm based in California announced in April 2010 that they were successful in developing this medication in alliance with GlaxoSmithKline(GSK).
- ↑ "ChemoCentryx Identifies Novel Small Molecule ChemR23 Antagonist for the Treatment of Inflammatory Diseases". Press Release. ChemoCentryx. 2010-04-10. http://www.chemocentryx.com/news/2010/pr20100408.html.